EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
1.14.11.29 | Anemia |
20973793 |
New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. |
causal interaction therapeutic application unassigned |
4 4 0 |
1.14.11.29 | Anemia |
21406036 |
HIF prolyl hydroxylase inhibitors for anemia. |
causal interaction therapeutic application unassigned |
4 4 0 |
1.14.11.29 | Anemia |
22262480 |
Pre-ischemic Targeting of HIF Prolyl Hydroxylation Inhibits Fibrosis associated with Acute Kidney Injury. |
therapeutic application unassigned |
2 0 |
1.14.11.29 | Anemia |
27438710 |
A mechanistic link between renal ischemia and fibrosis. |
causal interaction therapeutic application unassigned |
3 4 0 |
1.14.11.29 | Anemia |
28242135 |
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. |
causal interaction therapeutic application unassigned |
4 4 0 |
1.14.11.29 | Anemia |
28483447 |
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies. |
causal interaction therapeutic application unassigned |
4 4 0 |
1.14.11.29 | Anemia |
28651951 |
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. |
causal interaction therapeutic application unassigned |
4 4 0 |
1.14.11.29 | Anemia |
29485740 |
Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. |
causal interaction therapeutic application unassigned |
3 4 0 |
1.14.11.29 | Anemia |
29575006 |
First-in-man / proof of concept study with molidustat - a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. |
causal interaction therapeutic application unassigned |
1 4 0 |
1.14.11.29 | Anemia |
29909605 |
Anemia in conventional hemodialysis: Finding the optimal treatment balance. |
causal interaction therapeutic application unassigned |
3 4 0 |